Nasal spray for episodic cluster headache attacks
Treatments studied
Part of Brain & nervous system, Pain clinical trials.
This study tests an experimental nasal spray (zavegepant) for quickly stopping episodic cluster headache attacks. It's for people who have been diagnosed with episodic cluster headache and whose attacks usually last 45 minutes or more without treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of episodic cluster headache (a type of headache that comes in bouts).
- You must have had at least 2 separate bouts of cluster headaches before joining.
- Your cluster headaches must have started before you were 50 years old.
- Your typical untreated cluster headache attack lasts at least 45 minutes.
- You must be able to use a nasal spray device, read and speak English, and access the internet for study questionnaires.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether injections of botulinum toxin type A can reduce frequent, severe cluster headache attacks by targeting a facial nerve area. It’s for people whose cluster headaches have not responded well—or have caused side effects—to standard preventive treatments.
This study tests if a combination of pulsed radiofrequency and platelet-rich plasma can help people with episodic cluster headaches feel better during a cluster period. It is for people whose headaches are not well controlled with standard medicines.
This trial tests whether the medicine zavegepant (given as a nasal spray) is safe and works well for children aged 6 to 11 who have a history of migraines. If your child gets migraines, this study may help find a new treatment option.
This study tests how well a new acute migraine medicine, zavegepant, works and is tolerated in people who are already taking a CGRP-targeting preventive medication. It may help you find an effective treatment when you get a migraine attack.
This trial tests two new migraine medicines, rimegepant and zavegepant, given to people in the emergency department to see how well they work for stopping a migraine headache quickly.
This trial tests if eptinezumab can stop a migraine attack that is already happening. It may help people who get migraines often and are already part of the TACHIS study.
Hear when a new Cluster Headache trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.